Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Angiogenesis: possibilities for therapeutic interventions.

Literature DB >> 9972522

Angiogenesis: possibilities for therapeutic interventions.

W Wynendaele¹, A T van Oosterom, A Pawinski, E A de Bruijn, R A Maes.

Abstract

Vascular proliferation normally occurs only during embryonic development, the female reproductive cycle and wound healing. Various pathological conditions such as diabetic retinopathy are characterized by persistent, uncontrolled angiogenesis. At the other hand, impaired development of new blood vessels has been found to be related with myocardial infarction. A series of anti-angiogenic drugs are currently included in experimental cancer treatment, whereas the failure of ulcers to heal may be limited by increased angiogenesis upon administration of growth factors. In the present review control mechanisms of the vasculature are summarized and therapeutic approaches discussed.

Entities: Disease

Mesh：

Substances：

Year: 1998 PMID： 9972522 DOI： 10.1023/a:1008600603059

Source DB: PubMed Journal: Pharm World Sci ISSN： 0928-1231

Keyword Cloud
References

120 in total

Review 1. The inhibition of tumor growth by tumor mass.

Authors: R T Prehn
Journal: Cancer Res Date: 1991-01-01 Impact factor: 12.701

2. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function.

Authors: C D Venkov; A B Rankin; D E Vaughan
Journal: Circulation Date: 1996-08-15 Impact factor: 29.690

3. Scatter factor induces blood vessel formation in vivo.

Authors: D S Grant; H K Kleinman; I D Goldberg; M M Bhargava; B J Nickoloff; J L Kinsella; P Polverini; E M Rosen
Journal: Proc Natl Acad Sci U S A Date: 1993-03-01 Impact factor: 11.205

4. Inhibition of angiogenesis by suramin.

Authors: A Gagliardi; H Hadd; D C Collins
Journal: Cancer Res Date: 1992-09-15 Impact factor: 12.701

5. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development.

Authors: G Fontanini; S Vignati; D Bigini; M Lucchi; A Mussi; F Basolo; C A Angeletti; G Bevilacqua
Journal: Int J Cancer Date: 1996-09-04 Impact factor: 7.396

6. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells.

Authors: G T Stavri; Y Hong; I C Zachary; G Breier; P A Baskerville; S Ylä-Herttuala; W Risau; J F Martin; J D Erusalimsky
Journal: FEBS Lett Date: 1995-01-30 Impact factor: 4.124

Angiogenesis: possibilities for therapeutic interventions.

Review 1. The inhibition of tumor growth by tumor mass.

2. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function.

3. Scatter factor induces blood vessel formation in vivo.

4. Inhibition of angiogenesis by suramin.

5. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development.

6. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells.

7. Suppression of angiogenesis by the antitumor agent titanocene dichloride.

Review 8. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy.

9. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10.

10. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.